We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

According to UBS CEO Sergio Ermotti ... Novo Nordisk A/S (NYSE:NVO) is a healthcare company that researches, develops, manufactures, and distributes pharmaceutical products.

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Investing.com-- Economic growth in the Asia-Pacific region is likely to face headwinds in 2025 due to potential U.S. tariff increases, a strong dollar, and weaker export demand, UBS analysts said ...